Systemic sclerosis, an autoimmune disease of unknown origin, is characterized by progressive fibrosis that can affect all organs of the body. To date, there are no effective therapies for the disease. This paucity of treatment options is primarily because of limited understanding of the processes that initiate and promote fibrosis in general and a lack of animal models that specifically emulate the chronic nature of systemic sclerosis. Most models capitulate acute injury-induced fibrosis in specific organs. Yet, regardless of the model a major outstanding question in the field is the cellular origin of fibrosing cells.
INTRODUCTION
Fibrotic tissue is characterized by excessive deposition of extracellular matrix proteins including collagen and fibronectin, as well as increased numbers of fibroblasts expressing the contractile protein alpha smooth muscle actin (aSMA) within the interstitial spaces of tissues. Both these aberrant processes increase tissue stiffness. Uncorrected, these pathologic processes ultimately result in organ failure. In all forms of fibrosis, including systemic sclerosis (SSc), the major cell type considered to deposit excess collagen and smooth muscle actin is called the myofibroblast [1] . This term was given by Gabbini and colleagues to describe fibroblast-like cells present in granulation tissue that harbor extensive filamentous structures in their cytoplasm and exhibit deformed nuclei, evidencing cell contraction [2, 3] . The microfilametous contractile apparatus in these cells was later shown to contain myosin and aSMA, which subsequently became the primary marker for the cell type [4] . In addition to fibrosis, myofibroblasts are predominantly responsible for depositing collagenous scar tissue during wound healing, and their presence has been noted in association with epithelial tumors [5] . During wound healing, myofibroblasts ultimately undergo apoptosis resulting in scar resolution [5] . In fibrosis however, myofibroblasts persist, leading to progressive and chronic scar deposition. As myofibroblast presence is characteristic of all the forms of organ fibrosis, the criteria for a cell to be deemed fibrotic is the loss of its initial features and the acquisition of a myofibroblast phenotype. We will therefore primarily examine lineage-tracing studies that follow the fate of cells from various origins, outlined below, in the context of diverse organ fibrosis models.
Many studies on the origin of fibrotic cells have examined whether myofibroblasts arise from circulation or from resident cells within the afflicted tissue. Fibrocytes are hematopoietic cells that express markers in common with leukocytes, including CD45, CD11, CD18 and CD13 as well as some fibroblast markers including Vimentin and Collagen type 1 [6] . They also express CD34, a marker expressed by bone marrow progenitor cells, capillary endothelium, and fibroblasts [7] . Parabiosis and hematopoietic cell transplantation experiments indicate that resident stromal cells are the primary source of fibrosing cells and that fibrocytes support fibrosis progression. We highlight below the major evidence for the role of fibrocytes, and possible resident effector cells, including developmentally derived tissue fibroblasts, pericytes, adipocytes, epithelial cells, and endothelial cells ( 
FIBROCYTES
Fibrocytes have been considered a source of fibrosing cells, as they express Collagen 1 and display elevated numbers in acute wounds and fibrotic tissues [6] . Fibrocytes have been detected in approximately half of patients with systemic sclerosis (SSc)-associated interstitial lung disease and their presence was positively correlated with disease severity [36] . Intravenous delivery of CD45þ Col1þ fibrocytes into mice with TGFainduced lung fibrosis increased disease severity, whereas delivery of CD45-Col1-fibroblasts did not [37] . Additionally, fibrocytes have been shown to be elevated in patients with idiopathic pulmonary fibrosis and are mostly absent from healthy lungs [36, 38] . Most studies on fibrocytes have examined their role in bleomycin-induced lung fibrosis. In this model, it was recently observed that resident tissue fibroblasts actively secrete a factor that blocks fibrocyte differentiation from monocytes, the neuronal guidance protein Slit2 [39] . Injection of Slit2 led to a reduction of fibrocyte number in fibrotic lesions with a reduction of lesional collagen and overall fibrosis severity [39] . A previously discovered, liverderived factor called serum amyloidP also inhibits fibrocyte differentiation in vitro [40] and reduces fibrosis severity when injected in vivo [41] [42] [43] . It was, however, later suggested that the therapeutic effect may be attributed more to a reduction of activated M2 macrophage numbers in fibrotic lesions than the effect on fibrocytes specifically [42, 43] .
Despite the correlation between fibrocyte presence and fibrosis severity, a recent genetic ablation study [11 & ], in which the Col1a1 gene was deleted from cells expressing the pan-hematopoietic marker Vav1, suggested that fibrocytes are not major source of Collagen 1 in bleomycin-induced lung fibrosis. Although the authors observed that fibrocytes synthesized Collagen 1 at the transcript level, they found that CD45þ Col1þ fibrocytes produced far less Collagen 1 protein than CD45-Col1þ fibroblasts. Furthermore, the detection of intracellular Collagen 1 in fibrocytes using Vav1-Cre; Col1a1 floxed mice indicated that the majority of the intracellular Collagen 1 harbored by fibrocytes might be taken up from other cells rather than synthesized de novo. Additionally, fibrocytes were observed to be mostly negative for aSMA colocalization (less than 10%) in the TGFa-induced pulmonary fibrosis model [37] . In a recent kidney fibrosis study [16] , it was noted that although approximately 50% of aSMAþ myofibroblasts were bone marrow derived, ablation of circulatory fibroblasts had no impact on fibrosis severity. Other bone marrow-transplantation studies [8,12,16,20 & ,21] have shown that fibrosing cells derive from local sources and not from circulation. Collectively, these findings indicate that despite plausible importance of fibrocytes in mediating disease severity, fibrocytes are not a major fibrosing cell origin. It will be important in the future to elucidate the precise function of fibrocytes in the progression of fibrosis, specifically, how they facilitate increased deposition of extracellular matrix by myofibroblasts from other sources.
KEY POINTS
Recently defined lineages of resident tissue fibroblasts have the capacity to become myofibroblasts during injury and tumor formation, although it remains to be seen how they contribute to chronic fibrosis.
Lineage tracing studies indicate pericytes as a myofibroblast origin in diverse fibrosis models.
Adipocytes have recently been proposed as an origin of myofibroblasts in dermal fibrosis, reminiscent of hepatic stellate cell activation in liver fibrosis.
Studies examining the contribution of epithelial and/or endothelial cells to fibrosis suggest that these are not a primary source of fibrosing cells. 
DEVELOPMENTALLY DERIVED TISSUE FIBROBLASTS
A possible source of fibrosing cells is the resident fibroblasts that make up the connective tissue of organs during homeostatic conditions. In culture, fibroblasts are known to acquire myofibroblast markers in response to mechanical stimuli or treatment with signaling molecules such as TGFb1 or Wnt ligand [1] . Recent studies, however, have illuminated high heterogeneity within resident tissue fibroblast populations. Genetic lineage tracing wherein mice expressed Cre recombinase driven by the Dlk1 or Lrig1 promoters revealed that dermal fibroblasts arise developmentally from two separate lineages [8] . Dlk1-labeled stromal cells made up the majority of the lower dermis, whereas Lrig1-labeled cells constituted the upper dermis. During wound healing, Dlk1-traced fibroblasts infiltrated the wound bed and costained for a-smooth muscle actin, indicating myofibroblast transition, whereas Lrig1þ fibroblasts were observed within the wounded area during later stages of repair. Bone marrow transplantation revealed that there was no contribution of bone marrow derived cells to the wound fibroblasts, indicating that in dermal wound healing, 100% of the wound myofibroblasts derive from resident cells [8, 25] . Subsequently, two additional lineages of resident dermal fibroblasts have been identified, denoted by expression of Engrailed-1 in the dermis and Wnt1 in the oral dermis [9 & ]. These lineages were examined for their function in wound healing, radiation-induced fibrosis, and melanoma. Ablation of Engrailed-1-expressing fibroblasts using the diphtheria toxin system resulted in diminished collagen deposition in wounded skin and reduced expansion of fibroblasts associated with melanoma. Whether developmentally derived fibroblast lineages are distinct in adult tissue, and which of these lineages contribute to diverse fibrosis models will be important to define.
PERIVASCULAR STEM CELLS (INCLUDES MESENCHYMAL STEM CELLS AND PERICYTES)
Pericytes and mesenchymal stem cells are nonendothelial (CD31-), nonhematopoietic (CD45-) cells that reside in tight association with organ vasculature and have been implicated in fibrosis. Mesenchymal stem cells are defined by their ability to differentiate into many lineages in vitro, although there is much controversy over the specific markers they express [44] . Evidence suggests that these cells can be directed toward different fates in healthy versus pathologic conditions [24, 45] . Following skeletal muscle injury, for example, myogenic mesenchymal stem cells are shifted away from the myogenic fate and toward adipocyte or fibroblast fates [46] [47] [48] [49] [50] .
Pericytes reside directly adjacent to endothelial cells on the outer walls of blood vessels, and markers typically used to identify them include NG2, PDGFRb, CD135, Nestin, Desmin, and FoxD1 (Table  1) . Additionally, pericytes have been noted to share some myofibroblasts markers, including aSMA and Thy-1 [51] . Pericytes also demonstrate multilineage differentiation capacity in vitro and are therefore Lineage tracing Heart [35] considered to be somewhat synonymous with mesenchymal stem cells [44] . Although their function is not well understood, they seem to be required for vascular integrity, as their ablation leads to dilated vessels and hemorrhage [52] [53] [54] [55] . They are also increasingly considered important forerunners of fibrosing cells in acute tissue injury and fibrosis. Activated perivascular cells expressing PDGFRb have been observed in the dermis in association with the vasculature in skin biopsies from patients with earlystage systemic scleroderma and autoimmune Raynoud's syndrome, but not in healthy controls, primary Raynoud's, or late-stage scleroderma [56] . Perivascular cells are found in the perivascular space of every examined organ and are implicated in diverse fibrosis models. In injured skeletal muscle and ear dermis, perivascular cells lineage-traced from the ADAM12 promoter were found to proliferate and produce both aSMA and Collagen 1 [12] . As with resident fibroblasts during skin wound healing, these activated cells diminished as the injury resolved. Ablation of these cells led to a substantial decrease in fibrotic tissue formation [12] . Similarly, following spinal cord injury, pericytes were shown to disassociate from vasculature, proliferate, and express profibrotic proteins aSMA and Fibronectin [13,14 & ]. They were also required for injury resolution when traced from the Glast1 promoter [13] or Nestin promoter [14 & ].
The functional role of pericytes has been intensely examined in kidney fibrosis. Lineage tracing studies [10, 16, 17, 19, 21] from several promoters, including Cspg4 (NG2), PDGFRb, Col1a1, and FoxD1 have demonstrated the ability of pericytes to expand and differentiate into myofibroblasts in response to unilateral ureteral obstruction (UUO)-induced kidney fibrosis. Additionally, Foxd1-expressing pericytes follow this scheme in the context of bleomycin-induced lung injury [18] . In white adipose tissue fibrosis, induced by overactive PDGFRa signaling, pericytes lineage-traced from the Nestin promoter were shown to proliferate and acquire myofibroblast characteristics [15 & ]. Deletion of a vintegrin from PDGFRb-expressing pericytes in the lung and kidney attenuated fibrosis [19] suggesting a functional role for these cells as contributors to fibrosis. Ablation of NG2 or PDGFRb-labeled cells, however, did not ameliorate fibrosis in the kidney [16] .
A recent study [20 & ] described a class of Gli1þ, PDGFRb-expressing perivascular mesenchymal progenitor cells at the origin of fibrosis in diverse organs. Using genetic lineage tracing wherein tdTomato was expressed from the Gli1 promoter, the authors showed that Gli1-expressing perivascular cells are present in low numbers in the heart, kidney, liver, and lung and that they expand in fibrotic conditions. Concomitantly, ablation of Gli1expressing cells ameliorated fibrosis. Another study [14 & ], wherein pericytes were examined in different organ models of fibrosis, including lung, kidney, heart, spinal cord, and brain, suggested a functional distinction between Type 1 pericytes (defined as Nestin-, NG2þ) that accumulated with fibrosis progression, and Type 2 pericytes (Nestinþ, NG2þ), which did not expand.
Collectively, these studies indicate that perivascular cells make a substantial contribution to the formation of fibrotic tissue. Despite this, most studies indicate that they do not contribute 100% to the myofibroblast pool, implying that there are still other cellular origins. Additionally, it is still unclear to what extent these cells functionally contribute to fibrosis severity. In the future, it will be important to more fully understand the role of these cells under homeostatic conditions, to determine the extent of their contribution to fibrosis, and to elucidate the mechanisms that orient them toward the myofibroblast fate in pathological contexts.
ADIPOCYTES
Adipocytes have not been predominantly considered an important source of fibrosing cells in SSc, although there has been increasing evidence that they contribute to fibrosis. Strikingly, development of dermal fibrosis in SSc patients is accompanied by loss of subcutaneous adipocytes [57] , and this phenotype is well recapitulated in animal models of dermal fibrosis [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] . Loss of adipose tissue and its replacement with fibrous tissue have been observed in other pathologies as well, including cancer cachexia, epithelial tumors, and obesity [69] [70] [71] [72] . In the liver, trans-differentiation of lipidcontaining hepatic stellate cells into myofibroblasts is the primary driver of fibrosis [22, 27, 73, 74] . Therefore, a novel yet attractive model is that adipocytes or related lipid-containing cells may be an origin of fibrosis.
Using genetic lineage-tracing analysis wherein the Adiponectin promoter drove Cre-mediated expression of tdTomato, labeling mature adipocytes, Marangoni and colleagues [26 & ] recently observed that induction of fibrosis caused Adiponectin-expressing cells to trans-differentiate into a cell type resembling myofibroblasts, migrate into the dermis, and express aSMA. They also observed that dermal adipocytes were attenuated prior to increased collagen deposition and dermal thickness, and that a reduction of adipogenic gene expression preceded the increase in fibrotic gene expression. Interestingly, several therapeutic strategies shown Origin of fibrosing cells in systemic sclerosis Ebmeier and Horsley to ameliorate fibrosis in mice, such as treatment with TGFb neutralizing antibody or the PPARg agonist rosiglitazone, positively facilitate adipogenesis [59, 65, [75] [76] [77] [78] [79] . Future studies will elucidate whether adipocytes are essential to the development of fibrosis and whether this mechanism will apply to fibrosis in other organs.
EPITHELIAL CELLS
Epithelial to mesenchymal transition (EMT) has been considered a possible source of myofibroblasts in fibrosis, although this model has become less popular in light of most recent lineage-tracing studies. In the fibrosis context, the model was largely based on in-vitro studies [23, 28, [80] [81] [82] [83] showing that epithelial cells can express myofibroblast markers such as FSP1 and aSMA in response to TGFb stimulation. EMT is also known to support metastasis in epithelial cancers and is a key component of vertebrate development [82] . Lineage-tracing studies, however, examining EMT in fibrosis models have not strongly supported the contribution of epithelium to fibrotic cells. In liver fibrosis models, lineage tracing via albumin-Cre in hepatic epithelial cells yielded controversial results [23, 28] , and a subsequent study [29] in which hepatic epithelial cells were traced with promoter Alfp found no contribution of these cells to the myofibroblast pool. In UUO-induced kidney fibrosis, lineage tracing of gGT-expressing tubular epithelial cells suggested colocalization of labeled cells with myofibroblasts markers FSP1 and Hsp47 [30] , although later studies lineage tracing tubular epithelial cells via promoters Six2 and HoxB7 did not find any trace-labeled interstitial myofibroblasts [17] . Another UUO-induced kidney fibrosis study [16] tracing tubular epithelial cells with gGT-Cre found that only approximately 5% of myofibroblasts originated from these cells. In bleomycin-induced lung fibrosis, alveolar epithelial cells traced with the Sftpc or Scgbla1 promoters proliferated in fibrotic conditions; however, they did not stain positive for myofibroblasts markers S100A4, Vimentin, or aSMA and therefore were not shown to contribute to the fibrosis [31] .
ENDOTHELIAL CELLS
There is not strong evidence supporting a large contribution of endothelial cells to tissue fibrosis. In bleomycin-induced pulmonary fibrosis, cells marked by the pan-endothelial marker Tie2 were isolated and shown to upregulate myofibroblast genes aSMA and Col1a1 compared with cells from saline-treated mice [79] . Additionally, this group showed that endothelial cell lines could be induced to acquire a myofibroblast phenotype when treated with either TGFb or activated Ras, while losing expression of endothelial markers CD31, VE-cadherin, and CD34 [79] . In a cardiac fibrosis model, lineage tracing of another endothelial marker Tie1 showed colabeling of Tie1 with myofibroblast marker Fsp1, concomitant with similar loss of endothelial markers in labeled cells [35] . In the kidney, lineage tracing, in which YFP was expressed under control of either the Tie2 or Cdh5 promoter, also showed a contribution of endothelial cells to the fibrotic cellular pool [16, 34] .
Despite some arguments in favor of endothelial contributions in several forms of fibrosis, these studies are confounded by other evidence that Tie2 is expressed in not only endothelial cells but also other nonendothelial cell types, including nonendothelial mesenchymal stem cells [32] . Additionally, CD34 is not entirely specific for endothelium, as it also labels bone marrow stem cells, nonendothelial mesenchymal stem cells, subsets of dendritic cells, and dermal fibroblasts [7, 8] . Additional lineage-tracing studies using more specific Cre drivers that label endothelial cells, such as CD31 or VEcadherin, will be needed to determine if endothelial to mesenchymal transition actually contributes to fibrosis.
CONCLUSION
Identifying the origin of fibrosing cells has been a daunting task because of the diversity of cell types proposed, numerous organ fibrosis models, and the specificity and variable efficiency of labeling cell subsets in lineage-tracing studies. Although myofibroblasts producing aSMA and collagen are regarded as the principal effector cells, it should be considered that cells expressing either of these markers might contribute to increased extracellular matrix deposition and tension within fibrotic tissues.
Perivascular stem cells are increasingly being acknowledged for their capability to produce myofibroblasts in diverse models of injury and fibrosis. A future challenge will be to more fully identify markers to characterize these cells and to better understand their functions. Evidence in favor of contributions of diverse cell types, from endothelial cells to adipocytes to resident mesenchymal cells, is, however, being actively generated. It remains to be seen how interactions between fibrosing cells and other cell types affected by the process lead to disease progression. Currently, there are not effective therapies for the treatment of fibrosis, despite an abundance of molecular targets [84] . In the future, the development of new therapeutics able to specifically target the cells responsible for the deposition of extraneous collagen and expression of alpha smooth muscle actin will be needed to halt fibrosis progression while leaving by-standing cells intact, in the hopes that researchers can identify ways to regenerate tissue for a full recovery from fibrosis.
